Hybridon
Hybridon, Inc (Amex: HBY) was a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of novel therapeutics and diagnostics using synthetic DNA, that merged with Idera Pharmaceuticals in 2004.
Notable investors
According to a U.S. Securities and Exchange Commission filing of May 4, 1999[1] Hybridon had investors with 5% or more ownership including:
- Abdullah bin Mahfouz, son of the more widely known Khalid bin Mahfouz (13/87%), along with the Bermuda-based Mahfouz proprietary Intercity Holdings (13.87%);
- Yahia M. A. Laden (8.67%), half-brother of the more infamous Osama bin Laden;
- Nicris Limited, directed by Yehia bin Laden, and represented by Magnin Dunand et Associées (8.59%)
- Faisal Finance Switzerland, the first Islamic bank registered in Switzerland, and a fully owned subsidiary of Dar al-Maal al-Islami Trust, which was under investigation in 2007 by the U.S. Department of Justice in two separate terrorism financing probes.[2] (6.58%).
References
- ↑ DEFR14A for Hybridon, Inc, filed May 4, 1999
- ↑ Glenn R. Simpson (January 31, 2007). "Terror Inquiry Turns to Tax Law: Efforts to Probe Financing Of Islamic Extremists Centers on IRS Violations". Wall Street Journal. p. A3.
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.